Celltrion Valuation

Is A068270 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A068270 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
₩171.10k
Fair Value
4.0% overvalued intrinsic discount
21
Number of Analysts

Below Fair Value: A068270 (₩178000) is trading above our estimate of fair value (₩171100.55)

Significantly Below Fair Value: A068270 is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for A068270?

Key metric: As A068270 is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A068270. This is calculated by dividing A068270's market cap by their current revenue.
What is A068270's PS Ratio?
PS Ratio13.1x
Sales₩2.88t
Market Cap₩37.91t

Price to Sales Ratio vs Peers

How does A068270's PS Ratio compare to its peers?

The above table shows the PS ratio for A068270 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average18.9x
7.8x17.4%₩2.9t
A214450 PharmaResearch
8.9x22.7%₩2.9t
A298380 ABL Bio
58x25.5%₩2.0t
A006280 GC Biopharma
0.9x9.6%₩1.5t
A068270 Celltrion
13.1x26.0%₩37.9t

Price-To-Sales vs Peers: A068270 is good value based on its Price-To-Sales Ratio (13.1x) compared to the peer average (19.8x).


Price to Sales Ratio vs Industry

How does A068270's PS Ratio compare vs other companies in the KR Biotechs Industry?

26 CompaniesPrice / SalesEstimated GrowthMarket Cap
A006280 GC Biopharma
0.9x9.6%US$1.05b
A096530 Seegene
2.6x15.7%US$722.23m
A086900 Medy-Tox
3.3x13.8%US$548.52m
A005250 Green Cross Holdings
0.3xn/aUS$443.42m
A068270 13.1xIndustry Avg. 10.0xNo. of Companies26PS01632486480+
26 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: A068270 is expensive based on its Price-To-Sales Ratio (13.1x) compared to the KR Biotechs industry average (10x).


Price to Sales Ratio vs Fair Ratio

What is A068270's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A068270 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio13.1x
Fair PS Ratio8.4x

Price-To-Sales vs Fair Ratio: A068270 is expensive based on its Price-To-Sales Ratio (13.1x) compared to the estimated Fair Price-To-Sales Ratio (8.4x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A068270 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₩177,900.00
₩235,952.38
+32.6%
11.0%₩285,714.29₩152,380.95n/a21
Feb ’26₩179,700.00
₩236,564.63
+31.6%
11.2%₩285,714.29₩152,380.95n/a21
Jan ’26₩187,500.00
₩235,600.91
+25.7%
11.6%₩285,714.29₩152,380.95n/a21
Dec ’25₩178,095.24
₩233,832.20
+31.3%
13.2%₩285,714.29₩152,380.95n/a21
Nov ’25₩172,476.19
₩235,889.72
+36.8%
14.3%₩295,238.10₩142,857.14n/a19
Oct ’25₩186,095.24
₩236,892.23
+27.3%
13.3%₩295,238.10₩142,857.14n/a19
Sep ’25₩193,333.33
₩236,190.48
+22.2%
14.0%₩295,238.10₩142,857.14n/a19
Aug ’25₩190,476.19
₩228,095.24
+19.8%
14.6%₩285,714.29₩142,857.14n/a16
Jul ’25₩175,333.33
₩223,081.23
+27.2%
14.6%₩285,714.29₩142,857.14n/a17
Jun ’25₩167,809.52
₩220,840.34
+31.6%
12.5%₩285,714.29₩163,809.52n/a17
May ’25₩180,000.00
₩219,159.66
+21.8%
13.1%₩285,714.29₩163,809.52n/a17
Apr ’25₩179,142.86
₩210,588.24
+17.6%
13.9%₩285,714.29₩151,428.57n/a17
Mar ’25₩171,142.86
₩208,273.81
+21.7%
14.1%₩285,714.29₩151,428.57n/a16
Feb ’25₩170,190.48
₩212,063.49
+24.6%
12.4%₩285,714.29₩171,428.57₩179,700.0015
Jan ’25₩191,904.76
₩205,026.46
+6.8%
10.7%₩285,714.29₩171,428.57₩187,500.0018
Dec ’24₩155,333.33
₩206,613.76
+33.0%
10.9%₩285,714.29₩171,428.57₩178,095.2418
Nov ’24₩142,285.71
₩205,059.52
+44.1%
9.6%₩266,666.67₩171,428.57₩172,476.1916
Oct ’24₩132,571.43
₩200,280.11
+51.1%
13.5%₩266,666.67₩123,809.52₩186,095.2417
Sep ’24₩137,047.62
₩201,216.93
+46.8%
13.2%₩266,666.67₩123,809.52₩193,333.3318
Aug ’24₩143,809.52
₩206,050.42
+43.3%
13.4%₩266,666.67₩123,809.52₩190,476.1917
Jul ’24₩145,619.05
₩209,691.88
+44.0%
13.4%₩266,666.67₩123,809.52₩175,333.3317
Jun ’24₩167,047.62
₩208,665.04
+24.9%
13.0%₩266,666.67₩123,809.52₩167,809.5218
May ’24₩152,952.38
₩204,391.03
+33.6%
15.3%₩285,714.29₩123,809.52₩180,000.0016
Apr ’24₩142,666.67
₩207,605.31
+45.5%
16.6%₩285,714.29₩123,809.52₩179,142.8616
Mar ’24₩138,285.71
₩216,236.28
+56.4%
16.1%₩285,714.29₩137,362.86₩171,142.8616
Feb ’24₩161,714.29
₩217,953.62
+34.8%
16.2%₩285,714.29₩137,362.86₩170,190.4815
Analyst Price Target
Consensus Narrative from 21 Analysts
₩235.95k
Fair Value
24.6% undervalued intrinsic discount
21
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/13 15:19
End of Day Share Price 2025/02/13 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Celltrion, Inc. is covered by 41 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Girish BakhruBofA Global Research
Dae Woong YooBookook Securities Co. Ltd
Aaron HoCFRA Equity Research